SYSTIME

SystImmune is a clinical-stage biopharmaceutical company focused on developing next-generation multi-specific antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Headquartered in Redmond, Washington, the company leverages several proprietary platforms to create therapies that can simultaneously target multiple pathways involved in tumor growth and immune evasion. Their lead program, BL-B01D1, is a first-in-class bispecific ADC targeting EGFR and HER3, which is currently being evaluated in global Phase 3 clinical trials through a significant partnership with Bristol Myers Squibb. SystImmune's pipeline also includes novel tetra-specific T-cell engagers designed to treat various hematologic and solid malignancies. The company operates as the United States-based subsidiary of Sichuan Biokin Pharmaceutical.